New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
08:27 EDTNWBONorthwest Biotherapeutics reaffirms DCVax-Direct clinical trial interim data
Northwest Biotherapeutics announced that it refuted Adam Feuerstein's "latest false headline and attack on the company", reaffirming the company's recent interim data announcements from its Phase I/II clinical trial of DCVax-Direct for all inoperable solid tumors. The company added, "The Company's DCVax-Direct trial is ongoing. Contrary to Feuerstein's sensationalized false headline, the Company has not received a 'rebuke' from any clinical trial site, nor does the Company believe there is any basis for any such 'rebuke.' The company has consistently said that it would release interim data on an ongoing basis during the course of its DCVax-Direct Phase I/II trial. This trial is a single-arm, unblinded, 'open label; trial, meaning that all of the patients in the trial are receiving the DCVax-Direct treatment, and the clinical results in patients are visible to the Company as the trial goes along.
News For NWBO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
09:08 EDTNWBONorthwest Biotherapeutics begins first treatment with DCVax-L in Germany
Subscribe for More Information
October 7, 2014
09:07 EDTNWBONorthwest Biotherapeutics raises $11.5M through an institutional stock sale
Northwest Biotherapeutics announced that the Company has entered into an agreement with a single existing institutional shareholder for the purchase and sale of approximately $11.5M of newly issued shares of the Company's Common Stock at a price of $5.05 per share. H.C. Wainwright & Co., LLC acted as the sole placement agent for the transaction.
09:05 EDTNWBONorthwest Biotherapeutics enters into $11.5M financing agreement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use